 DURHAM, N.C.--BUSINESS WIRE--- DTIL ARCUS--Precision BioSciences, Inc. Nasdaq: DTIL, a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene Cell Therapy ESGCT for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre. Oral Presentation: Title: Targeting the hepat 